FDA stays tuned to Taxus adverse events
This article was originally published in The Gray Sheet
Executive Summary
Agency pledges to keep the public apprised of complaints related to the Boston Scientific paclitaxel-eluting stent, but says collected data detailing 28 Taxus incidents to date are insufficient to justify a formal solicitation similar to last October's "web notification" about J&J/Cordis' Cypher thrombosis rates. Some physicians have reported that the Taxus delivery system resists extraction after stent deployment, possibly due to improper balloon deflation. The incident rate is about 11.8 complaints per 1,000 used, Boston Scientific says, attributing the problems to physicians unfamiliar with the system (1"The Gray Sheet" April 26, 2004, p. 5)...
You may also be interested in...
Changes to Taxus manufacturing
FDA approves special PMA supplement May 5 for Boston Scientific to modify the laser bonding process used to unite the drug-eluting stent's delivery catheter and balloon prior to packaging. The move responds to physician complaints about the balloon not deflating properly or sticking to the stent coating during removal (1"The Gray Sheet" May 3, 2004, In Brief). A recall will not be initiated, the company says, claiming the best way to avoid potential problems with existing stents is to follow the instructions for use, specifically concerning inflation and deflation timing and pressure. Boston Scientific attributes the issues to physicians being unfamiliar with the system. FDA does not plan to formally address the issue; however, the agency notes its will provide communications if further problems arise...
Cypher, Taxus Perform Equally Well In Trials, Registries – Meier Analysis
The overall clinical performance of Boston Scientific's Taxus and J&J/Cordis' Cypher drug-eluting coronary stents is practically equivalent, according to Bernard Meier, MD, University Hospital, Bern, Switzerland
Boston Scientific To Study Complex DES Use; Taxus Complaints Surface
Boston Scientific is maintaining a "sober" outlook regarding its chances of obtaining increased reimbursement in the near-term for multi-vessel interventions using drug-eluting stents